Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.

Communications biology - 16 Dec 2020

Somwar Romel, Hofmann Nicolle E, Smith Bryan, Odintsov Igor, Vojnic Morana, Linkov Irina, Tam Ashley, Khodos Inna, Mattar Marissa S, de Stanchina Elisa, Flynn Daniel, Ladanyi Marc, Drilon Alexander, Shinde Ujwal, Davare Monika A

Abstract excerpt

Tyrosine kinase domains dynamically fluctuate between two main structural forms that are referred to as type I (DFG-in) or type II (DFG-out) conformations. Comprehensive data comparing type I and type II inhibitors are currently lacking for NTRK fusion-driven cancers. Here we used a type II NTRK inhibitor, altiratinib, as a model compound to investigate its inhibitory potential for larotrectinib (type I...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Molecular Conformation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oncogene Proteins, Fusion

Share to Protein Interaction Domains and Motifs

Share to Receptor, trkA

Share to Receptor, trkC

Share to Structure-Activity Relationship

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 33328556
DOI: 10.1038/s42003-020-01508-w
PMCID: PMC7745027

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.PMID 33328556Read ↗

Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinibSemantic proximity Read ↗

TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.Semantic proximity Read ↗

Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations.Semantic proximity Read ↗

The resistance tetrad: amino acid hotspots for kinome-wide exploitation of drug-resistant protein kinase alleles.Semantic proximity Read ↗

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidenceSemantic proximity Read ↗

Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations.Semantic proximity Read ↗

Safety of current treatment options for NTRK fusion-positive cancersSemantic proximity Read ↗

Landscape of drug-resistance mutations in kinase regulatory hotspotsSemantic proximity Read ↗

Responsiveness of different MET tumour alterations to type I and type II MET inhibitors.Semantic proximity Read ↗

TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults.Semantic proximity Read ↗

Targeting Gatekeeper Mutations for Kinase Drug DiscoverySemantic proximity Read ↗

Overcoming Secondary Mutations of Type II Kinase Inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.